Everolimus‐Eluting Stents Versus Sirolimus‐ or Paclitaxel‐Eluting Stents: Two‐Year Results from the Guthrie Health Off‐Label Stent (GHOST) Registry

Harjai, Kishore J.; Kondareddy, Sreekanth; Pinkosky, Brian; Harjai, Neil; Orshaw, Pam; Boura, Judy

doi:10.1111/j.1540-8183.2013.12016.x

Cited by 18 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have demonstrated the superiority of DES over BMS regarding the need for target-lesion revascularisation [10][11]. In agreement with previous research, in our study, BMS-ISR was significantly more frequent than DES-ISR, but without significant betweenstudy-group differences.…”

Section: Resultssupporting

confidence: 92%

Clinical and Stent-related Risk Factors for Recurrent Angina After Successful Percutaneous Coronary Intervention

Dinesch¹,

Dinesch²,

Buruian³

2019

Rev. Chim.

View full text Add to dashboard Cite

We evaluated the clinical and stent-related risk factors for recurrent angina (RA) symptoms after percutaneous coronary intervention (PCI), as identifying and treating them could improve patient outcomes. We retrospectively analysed patients readmitted at our clinic after successful PCI; 147 (81.66%) patients were hospitalised for RA. Advanced age was associated with RA symptoms. Drug-eluting stents used at the index PCI, especially in small coronary arteries, seemed protective against RA symptoms. In-stent restenosis, which was associated with RA, was more frequent in bare-metal stents than in drug-eluting stents. Further studies are needed to identify other potential risk factors for RA and to determine how to positively influence the evolution of known risk factors.

show abstract

Section: Resultssupporting

confidence: 92%

Clinical and Stent-related Risk Factors for Recurrent Angina After Successful Percutaneous Coronary Intervention

Dinesch¹,

Dinesch²,

Buruian³

2019

Rev. Chim.

View full text Add to dashboard Cite

show abstract

“…Clinical data show the superiority of newer DES in terms of TLR, myocardial infarction and stent thrombosis (ST) (18,19).…”

mentioning

confidence: 99%

Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment

et al. 2016

View full text Add to dashboard Cite

“…Whereas in the second group of SG-EES vs. FG-PES less major adverse cardiovascular events were observed (MACE) meaning including death events and myocardial infarction events. In both groups no ST was observed in the EES after the first 3 months [75]. The same positive results were observed with 317 patients again with EES and FG-DESs in another study applying these stents in saphenous vein graft lesions [76].…”

Section: Everolimusmentioning

confidence: 70%

Learning from the Cardiologists and Developing Eluting Stents Targeting the Mtor Pathway for Pulmonary Application; A Future Concept for Tracheal Stenosis

Darwiche

Tsakiridis²,

Teschler

et al. 2013

J Mol Genet Med

View full text Add to dashboard Cite

Tracheal stenosis due to either benign or malignant disease is a situation that the pulmonary physicians and thoracic surgeons have to cope in their everyday clinical practice. In the case where tracheal stenosis is caused due to malignancy mini-interventional interventions with laser, apc, cryoprobe, balloon dilation or with combination of more than one equipment and technique can be used. On the other hand, in the case of a benign disease such as; tracheomalacia the clinician can immediately upon diagnosis proceed to the stent placement. In both situations however; it has been observed that the stents induce formation of granuloma tissue in both or one end of the stent. Therefore a frequent evaluation of the patient is necessary, taking also into account the nature of the primary disease. Evaluation methodologies identifying different types and extent of the trachea stenosis have been previously published. However; we still do not have an effective adjuvant therapy to prevent granuloma tissue formation or prolong already treated granuloma lesions. There have been proposed many mechanisms which induce the abnormal growth of the local tissue, such as; local pressure, local stress, inflammation and vascular endothelial growth factor overexpression. Immunomodulatory agents inhibiting the mTOR pathway are capable of inhibiting the inflammatory cascade locally. In the current mini-review we will try to present the current knowledge of drug eluting stents inhibiting the mTOR pathway and propose a future application of these stents as a local anti-proliferative treatment.

show abstract

Everolimus‐Eluting Stents Versus Sirolimus‐ or Paclitaxel‐Eluting Stents: Two‐Year Results from the Guthrie Health Off‐Label Stent (GHOST) Registry

Abstract: The use of EES compared to FG-DES appears to be associated with reductions in ST and TVR at 2-year follow-up. Improved outcomes with EES are observed in comparison with SES as well as PES.

Cited by 18 publications

References 36 publications

Clinical and Stent-related Risk Factors for Recurrent Angina After Successful Percutaneous Coronary Intervention

Clinical and Stent-related Risk Factors for Recurrent Angina After Successful Percutaneous Coronary Intervention

Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment

Learning from the Cardiologists and Developing Eluting Stents Targeting the Mtor Pathway for Pulmonary Application; A Future Concept for Tracheal Stenosis

Contact Info

Product

Resources

About